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With almost a dozen vaccine candidates in clinical trials, tuberculosis (TB) research and development is
finally reaping the first fruits of its labors. Vaccine candidates in clinical trials may prevent TB disease reac-
tivation by efficiently containing the pathogen Mycobacterium tuberculosis (Mtb). Future research should
target vaccines that achieve sterile eradication ofMtb or even prevent stable infection. These are ambitious
goals that can be reached only by highly cooperative engagement of basic immunologists, vaccinologists,
and clinical researchers—or in other words, by translation from basic immunology to vaccine research and
development, as well as reverse translation of insights from clinical trials back to hypothesis-driven research
in the basic laboratory. Here, we review current and future strategies toward the rational design of novel
vaccines against TB, as well as the progress made thus far, and the hurdles that need to be overcome in
the near and distant future.Introduction
A total of 11 vaccine candidates against tuberculosis (TB) have
entered clinical trials within the last several years (Box 1; Kauf-
mann et al., 2010; StopTB Partnership Working Group on New
TB Vaccines, 2009). Many of them look promising. Yet, in none
of these cases do we know with certainty whether they will
confer robust protection against TB in humans. A widely held
view considers infection synonymous with disease, i.e., we
consider disease the unequivocal sequelae of infection with
a pathogen. The so-called childhood diseases are testament to
this view and include measles, mumps, rubella, diphtheria, and
tetanus. Moreover, we are used to expecting virtually 100%
protection from our experience with vaccines against such
diseases, because we consider sterile eradication a prerequisite
for cure (Kaufmann, 2009).
For TB, the situation ismore complex. Infection withMycobac-
terium tuberculosis (Mtb) does not necessarily lead to active TB
disease (Kaufmann, 2006b). Most infected individuals remain
healthy. However, they do not achieve sterile eradication of the
pathogen and consequently remain latently infected lifelong. It
has been estimated that 1/3 of the world population, i.e., some-
where around 2.2 billion individuals on this globe, are latently
Mtb infected (Figure 1; WHO, 2009; Lo¨nnroth et al., 2010).
A vaccine, therefore, is not needed for 90% of individuals if
one is satisfied with prevention of TB disease reactivation and
accepts latent Mtb infection. It is the 10% of individuals at risk
of developing disease who represent the targets for novel
vaccines against TB. Under these circumstances, future vac-
cines are satisfactory if they induce an immune response in
susceptible individuals comparable to that evoked by natural
Mtb infection in resistant ones. Alternatively, if one aims at sterile
Mtb eradication, future vaccines need to perform better than
natural immunity in resistant individuals, which only contains
infection.All current pre-exposure TB vaccine candidates in clinical
trials at most will achieve prevention of TB reactivation, not
sterile eradication (Kaufmann et al., 2010; StopTB Partnership
Working Group on New TB Vaccines, 2009). Therefore, long-
lasting, if not lifelong, protection is required. This is not a given
because both endogenous and exogenous insults can deterio-
rate vaccine-induced immunity. For example, coinfection with
helminths or HIV could reorient or impair the ongoing immune
response, respectively (Weir et al., 2006; Azzopardi et al.,
2009; Hesseling et al., 2007b). In Sub-Saharan Africa where TB
rampages most, virtually everybody is infected by helminths
and HIV infections are common (Harries et al., 2010; Hotez and
Kamath, 2009). Very little is known about how vaccine-induced
immunity deals with coinfections. Equally little is known about
the factors that determine whether or not an individual is
protected against natural infection with Mtb (the 2.2 billion
individuals on this globe) or whether someone is at risk of devel-
oping TB at a later stage (the 10 million who develop active TB
annually).
As a first step in TB vaccine research and development
(R&D), we need to understand whether the immune response,
which operates in latently infected, resistant individuals, can be
induced in susceptible individuals. Deeper insights could be
obtained by biomarkers, which distinguish the host response
in latently infected healthy individuals, from those who develop
TB disease (Parida and Kaufmann, 2010). Comparative tran-
scriptome and metabolome analyses indicate that such bio-
markers can be identified (Parida and Kaufmann, 2010). Yet, is
it sufficient to be as good as nature or do we need to do better?
It is most likely that as a next step in the TB vaccine R&D pipeline
and beyond, we need to do better than nature because in
a world threatened by HIV, the immune response induced by
natural infection or by vaccination is frequently impaired by HIV
coinfection, thereby facilitating TB disease reactivation. In fact,Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 567
Figure 1. The Vicious Cycle of TB
The figure depicts daily numbers of infections with Mycobacterium tubercu-
losis (Mtb), new cases of TB, cases of death because of TB, and numbers
of latently Mtb-infected individuals, new TB cases annually, and TB deaths
annually.
Box 1. The Three Phases of Clinical Trials for TB Vaccines
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whom annually 1 million develop TB disease leading to half
a million deaths (Kaufmann et al., 2010). Complementing this
disaster are the increasing incidences of multidrug-resistant
(MDR) TB and extremely resistant (XDR) TB (Gandhi et al., 2010).
Fast-Track Overview of the Immune Response in TB
Generally, Mtb enters the host within aerosols inhaled to the
lungs. Minute droplets of 1–3 mm containing few tubercle bacilli
arrive at the deeper alveoli where they are engulfed by alveolar
macrophages. Some bacilli are deposited in the lung paren-
chyma and some are transported to draining lymph nodes where
dendritic cells (DCs) prime T lymphocytes.Mtb persists in mono-
nuclear phagocytes and DCs where it hides (Russell, 2007). The
pathogen accomplishes intracellular survival through several
evasion strategies including neutralization of the phagosomal
pH and interference with autophagy, which serves as a cell-
autonomous defense mechanism (Gutierrez et al., 2004; Deretic,
2006; Russell, 2007). Moreover, Mtb can invade the cytosolic
compartment (van der Wel et al., 2007). Finally, Mtb inhibits
apoptosis by production of prostaglandins (Divangahi et al.,
2010). During this early stage, Mtb may be transported to other
sites within infected macrophages (Davis and Ramakrishnan,
2009).
Evidence fromamodel system suggests benefit forMtb during
early stages of granuloma formation (Cosma et al., 2008).
Consistent with this, the mycobacterial virulence factor ESAT-6
promotes accumulation of macrophages at the sites of inflam-
mation (Volkman et al., 2010).
Under the influence of specific T lymphocytes, the loose
aggregates ofmononuclear phagocytes and polymorphonuclear
granulocytes transform into solid granulomas composed of
macrophages of different activation and maturation stages and568 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.different T cell populations in a structured arrangement (Figure 2;
Ulrichs and Kaufmann, 2006).Within these solid granulomasMtb
is contained but not eradicated. As a corollary, latent infection
ensues but disease is prevented. Recent evidence suggests
that TB granulomas can acquire lymphoid functions. In the
absence of secondary lymphoid organs, granulomas can serve
as sites for priming of CD4+ and CD8+ T cells as well as germinal
center B cells. Notably, primed T cells are polyfunctional,
express markers of central memory T (Tcm) cells, and provide
protective immunity against TB in an experimental mouse model
(Day et al., 2010).
With the failure of the immune response to contain Mtb,
necrotic areasmay develop and later become caseous. Although
it is clear that cavitation is caused by an aberrant immune
response, both hypo- and hyperactive immunity can be the
cause. Ultimately,Mtb grows to enormous numbers in the order
of magnitude of 1012–1014. Exuberant damage to the lung, Mtb
dissemination to other organs, and spread of the contagion in
the environment are reflections of active TB disease.
During residence in phagosomes, Mtb secretes proteins,
which after appropriate degradation can be loaded onto prod-
ucts of the major histocompatibility complex (MHC) class II.
This leads to CD4+ T cell stimulation. Mechanisms underlying
CD8+ T cell stimulation are not fully understood. This requires
peptide presentation byMHC I products, which generally occurs
in the cytosol not readily accessed by Mtb. Two pathways have
been proposed. First,Mtb can egress into the cytosol of infected
DCs, and this leads to direct loading of MHC Imolecules (van der
Wel et al., 2007). Second, crosspriming has been observed
(Winau et al., 2006). This process comprises apoptosis of macro-
phages infected with Mtb. Resulting vesicles carry mycobacte-
rial antigens, which are taken up by DCs in the vicinity (Winau
et al., 2005). These DCs present antigenic peptides with high effi-
cacy both in the context of MHC II and MHC I to CD4+ and CD8+
T cells, respectively. Again, however, Mtb can interfere with
these processes of antigen presentation. First, Mtb inhibits
MHC class II processing and thus impairs CD4+ T cell stimulation
Figure 2. The Pathologic and Cellular Basis
of the Host Response in TB
The immune response at the different stages of the
vicious cycle of TB. After infection of the host in the
lung, macrophages and DCs stimulate specific
CD4+ and CD8+ T cells, which are critical for
protection againstMtb. CD4+ T cells are polarized
into Th1 and Th17 cells, which perform effector
functions. CD8+ T cells contribute to protection
by cytolytic mechanisms and IFN-g production.
As a next step,memory T cells develop. Coexpres-
sion of multiple cytokines, notably IL-2, TNF, and
IFN-g, is considered as indicator of protective
CD4+ memory T cells, and coexpression of cyto-
lytic molecules, together with IFN-g and TNF,
is considered characteristic for CD8+ memory
T cells. Confounding factors include exogenous
invaders (e.g., HIV, helminths) as well as endoge-
nous cytokines (IL-4, IL-10, TGF-b) and inhibitory
surface molecules (CTLA4, PD-1), which have the
potential of disturbing the immune response.
Accordingly, the outcome of immunity may vary.
Abbreviations: Teff, effector T cell; CTL, cytolytic
T lymphocyte; Th, T helper cell; M4, macrophage;
TNF, tumor necrosis factor; IFN-g, interferon
gamma; TGF-b, transforming growth factor beta;
IL, interleukin; MHC, major histocompatibility
complex; PNG, polymorphonuclear granulocyte.
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CD8+ T cells through modulating the lipoxygenase pathway
(Divangahi et al., 2010).
Stimulation through pattern recognition receptors (PRR)
expressed on the surface of DCs and macrophages instructs
CD4+ T cell polarization (Akira et al., 2006). These include Toll-
like receptors (TLR), C-type lectin receptors (CLR), and others
(Dorhoi and Kaufmann, 2009). The TLR2 recognize glycolipids
such as certain lipomannan (LM) cognates from Mtb and the
TLR9 recognize CpG motifs of Mtb DNA (Akira et al., 2006).
The CLR include DC-SIGN, which binds LM, and Mincle, which
binds trehalose dimycolate (TDM) (Schoenen et al., 2010; Ishi-
kawa et al., 2009). Sensing of different molecular patterns
through a range of PRR stimulates signaling cascades that are
assembled in adaptors including MyD88 and Card9, which
then emit signals, which instruct T cells (Dorhoi and Kaufmann,
2009; Dorhoi et al., 2010). Generally, signaling through TLR
and Mincle promotes type 1 T helper (Th1) cells, Dectin-1 and
Mincle favor Th17 cells, and DC-SIGN induces suppression or
exhaustion (Schoenen et al., 2010; Ishikawa et al., 2009; Tailleux
et al., 2003; Geijtenbeek et al., 2003; Dennehy et al., 2009;
Underhill et al., 1999).
Th1 cells produce amultitude of cytokines, notably, interleukin
(IL)-2, interferon-gamma (IFN-g), and lymphotoxin (LT), and
tumor necrosis factor (TNF) and are critical for protection
(Figure 2; Cooper, 2009). Although the role of Th17 cells in TB
remains to be fully clarified, they seem to play an important
role in the early formation of protective immunity in the lung
(Khader et al., 2007; Cooper, 2009; Kaufmann, 2006b).
Th2 cells counter-regulate Th1 cells and in this way probably
impair protective immunity in TB. Treg cells produce transform-ing growth factor-beta (TGF-b) and IL-10, which suppress all
T cell populations (Belkaid and Tarbell, 2009; Chen et al., 2007;
Guyot-Revol et al., 2006; Dlugovitzky et al., 1999). TGF-b is
also involved in the formation of the fibrotic wall surrounding
granulomas in TB (Toossi and Ellner, 1998).
The MHC class I-restricted CD8+ T cells contribute to protec-
tive immunity against TB (Kaufmann, 2006a; Cooper, 2009).
These CD8+ T cells secrete perforin and granulysin, which lyse
host cells and attack Mtb directly (Stenger et al., 1997, 1998).
After the first wave of effector T (Teff) cells, the immune response
contracts and Teff cells are succeeded by memory T cells (Fig-
ure 2; Williams and Bevan, 2007; Sallusto et al., 2004). The
memory T cells of Th1 type are polyfunctional, i.e., a single
T cell clone produces multiple cytokines, notably IL-2, IFN-g,
and TNF (Foulds et al., 2006). These polyfunctional CD4+ mem-
ory T cells are considered crucial mediators of long-term pro-
tection against TB (Foulds et al., 2006; Sutherland et al., 2010).
Similarly, CD8+ memory T cells develop. The memory T cells
further segregate into Tcm and effector memory T cells (Tem),
the former being characterized by preferential homing to lymph
nodes and the latter by preferential residence in tissue sites
such as the Mtb-infected lung parenchyma (Figure 2; Sallusto
et al., 2004; Mora and von Andrian, 2006).
During containment in the latently infected healthy individual,
Mtb faces a stress situation notably imposed by hypoxia and
nutrient deficiency. In vitro data suggest that such conditions
lead to transformation into a dormant stage with low to absent
metabolic and replicative activity (Betts et al., 2002; Voskuil
et al., 2003; Wayne and Sohaskey, 2001). Accordingly, antigens
produced by dormant Mtb are called dormancy antigens.
Among these are the 48 gene products controlled by DosR,Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 569
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hypoxia. Dormancy antigens could represent major immune
targets during latent infection (Black et al., 2009; Schuck et al.,
2009; Leyten et al., 2006; Lin and Ottenhoff, 2008).
The dormant pathogen is highly resistant to immune attack.
Eventually, the immune response is downmodulated to avoid
collateral damage but still suffices for Mtb control. Aberrant
immunity, e.g., through exhaustion or suppression of T cells,
tips the balance in favor of the pathogen. Two major types
of mechanisms have been described in other models. First,
cognate interactions between T cells and DCs involving the pro-
grammed death (PD)-1-PD-L system or the CTLA-4 and B7.1-
B7.2 systems lead to T cell exhaustion (Keir et al., 2008; Cham-
bers et al., 2001; Jurado et al., 2008). Second, Treg cells secrete
regulatory cytokines, notably IL-10 and TGF-b, which suppress
ongoing immune responses (Belkaid and Tarbell, 2009). Princi-
pally, Treg cells express CD25, the high-affinity receptor for
IL-2. CD25 can be shed into the circulation where it serves as
decoy factor that removes IL-2, resulting in diminished T cell
activity because of insufficient IL-2 availability (Shitrit et al.,
2006; Rubin et al., 1985; Kursar et al., 2007). Once aberrant
immune responses arise, Mtb are resuscitated from a dormant
to metabolically active stage (Leyten et al., 2006; Kana et al.,
2008). This reactivation leads to active TB.
In sum, we do not exactly know which types of T cells are
needed for containment of Mtb: Teff, because ‘‘trench warfare’’
takes place, or memory T cells, because long-term immunity is
required. Among Teff, do we need CD4+ Th1 cells, CD4+ Th17
cells, CD8+ CTL, or all of them, with additional help from uncon-
ventional CD1-restricted T cells and gd T cells (Cooper, 2009;
O’Shea and Paul, 2010; Brigl and Brenner, 2004; Scotet et al.,
2008)? Among memory T cells, do we need Tem cells, which
are active at the site of Mtb containment, i.e., solid granulomas
in the lung, or Tcm cells, residing in draining lymph nodes that
constantly generate Teff cell progeny? We need to learn which
combinations of T cell subsets and which cytokine ‘‘gemisch’’
are required. We also need to make a register of antigens ex-
pressed by Mtb during stages of dormancy, resuscitation, and
activity. Finally, we need to know whether Mtb hides only in
macrophages within granulomas or also in mononuclear phago-
cytes at other tissue sites, or even in other cells, i.e., nonprofes-
sional phagocytes. Thus, even canonical vaccine candidates are
surrounded by numerous unknowns. They are, at least in part,
‘‘knowable unknowns’’ and we urgently need to clarify these.
Current Situation
The current vaccine against TB, namely, Bacille Calmette-Gue´rin
(BCG), has been given 4 billion times over the last 90 years (Kauf-
mann et al., 2010). Yet available evidence suggests that this
vaccine does not protect against adult pulmonary TB. It protects
against severe disease in infants, and to a lesser extent against
lung TB in infants (Kaufmann et al., 2010; Fine, 1995). BCG-
induced protection, however, wanes with age. Large studies
have shown very limited efficacy of revaccination with BCG in
adolescents and adults (Antas and Castello-Branco, 2008).
A recent field study has exploited the observation that BCG
induces variable protection in infants, by investigating correlates
of risk of TB disease after routine BCG vaccination. These
studies determined that mycobacteria-specific T cell expression570 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.of IFN-g, or of many other combinations of Th1 cytokines
10 weeks after newborn BCG vaccination, does not predict
risk of TB disease (Kagina et al., 2010). These data emphasize
that the precise immune mechanisms of protection elicited by
BCG remain incompletely understood. In other words, almost
90 years after the first administration of BCG to a baby and
more than 100 years since its development, we don’t even
understand the precise immune mechanisms that protect BCG-
vaccinated infants (Calmette, 1927; Fine, 1995; Kaufmann et al.,
2010).
Vaccine Candidates in Clinical Trials
Of the 11 vaccine candidates currently in clinical trials, two are
killed myobacteria or semipurified mycobacterial components
for adjunct therapy of HIV-Mtb-coinfected individuals (Kaufmann
et al., 2010; StopTB Partnership Working Group on New TB
Vaccines, 2009). These will not be discussed further. The re-
maining nine candidates are preventive pre-exposure vaccines,
i.e., given prior toMtb infection (Box 2). The goal of these candi-
dates is the containment of Mtb so that latent infection is sus-
tained and TB disease reactivation is prevented or at least
delayed. Two of these vaccine candidates should replace
conventional BCG. Both are recombinant (r)BCG constructs,
which induce superior protection compared to BCG in preclinical
animal models. The other seven candidates are subunit booster
vaccines to be given on top of the BCG prime. Therefore, they
improve or reorient the immune response evoked by BCG. These
subunit vaccines comprise a small set of secreted antigens,
i.e., proteins secreted by metabolically activeMtb. Three candi-
dates harness viral carriers while the other four are protein plus
adjuvant formulations. The frequently used antigen 85 (Ag85)
cognates, Ag85A or Ag85B, which are most widely used in the
current vaccine candidates, are shared by BCG and Mtb and
hence evoke a true booster response. Additional antigens that
are unique to Mtb and therefore do not represent true booster
antigens are ESAT6 or TB10.4. They are encoded within the
region of difference 1 (RD-1) gene cluster, which is present in
Mtb and absent in BCG (Dietrich et al., 2005).
Subunit Vaccines for Booster of BCG
Currently, two viral carriers are being harnessed for TB vaccines:
modified vaccinia virus Ankara (MVA) developed by Oxford
University and replication-deficient Adenovirus (Ad) of serotype
5 or 35 (Ad5 created by McMaster University and Ad35 created
byCrucell and Aeras) (Sander et al., 2009; Radosevic et al., 2007;
McShane et al., 2004; Santosuosso et al., 2006). The MVA and
Ad5 virus carriers both express Ag85A whereas the Ad35 coex-
presses the antigens Ag85A, Ag85B, and TB10.4. Infections with
Ad occur frequently. Accordingly, antibodies exist in many
humans (Bangari and Mittal, 2006). This is particularly true for
Ad5 but less so for Ad35. Yet, up to 20%of people living in Africa
have Ad35-specific antibodies. These pre-existing antibodies
could impair Ad-based vaccine efficacy, but evidence arguing
against impact of these preexisting antibodies on vaccine
efficacy has been obtained from vaccination trial with an Ad5
HIV-1 vector (Hutnick et al., 2009; O’Brien et al., 2009).
New virus carriers in development include simian Ad vectors
and lymphocytic choriomeningitis virus (LCMV) (Hill et al.,
2010; Flatz et al., 2010). Simian Ad do not infect humans and
Box 2. Approaches to TB Vaccine R&D
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an issue (Hill et al., 2010). The LCMV vector is a potent stimulator
of Th1 CD4+ T cells and of neutralizing antibodies (Flatz et al.,
2010).
Three different types of adjuvants are currently used for protein
vaccines. The adjuvant IC31 developed by Intercell has been
used in combination with Hybrid1 (H1) by Statens Serum Institut
(SSI), which is a fusion protein of Ag85B andESAT6, or combined
with HyVac4 from SSI, which is a fusion protein of Ag85B and
TB10.4 (Dietrich et al., 2005; van Dissel et al., 2010). IC31
comprises a cationic antimicrobial peptide (KLKL5KLK) and an
oligodeoxynucleotide (ODN), which is not a CpG, yet binds to
TLR9 (Lingnau et al., 2007). The cationic peptide increases
antigen uptake by APC and provides a depot for slow antigen
release. The ODN stimulates both myeloid and plasmacytoid
DCs. IC31 induces CD4+ Th1 cells and CD8+ cytolytic T lympho-
cytes (CTL) as well as antibodies. GlaxoSmithKline (GSK) has
designed an adjuvant platform for new vaccines composed of
distinct building blocks for different requirements (Reed et al.,
2009). AS01 and AS02 have been selected for TB vaccines and
currently AS01 is favored for further clinical development (Von
Eschen et al., 2009). Both AS cognates contain monophosphoryl
lipid A (MPLA), which stimulates Th1 cells and probably Th17
cells through TLR4 signaling and the surface-active compound
QS-21,which facilitatesCD8+CTLstimulation. TheAS01 isa lipo-
somal formulation whereas AS02 is an oil-in-water emulsion.
Both systems form depots for slow antigen release and AS01apparently is a stronger stimulator of Th1 over Th2 cells whereas
AS02 seems to stimulate both T cell populations equally. The
antigen in this vaccine (termed M72) is a fusion protein of the
antigens Rv1196 and Rv0125 (Von Eschen et al., 2009). Most
recently, the CAF01 adjuvant developed by SSI has been formu-
latedwith antigenH1, also fromSSI. CAF01 is a liposomal formu-
lation composed of dimethyldioctadecyl ammonium bromide
(DDA) and trehalose 6,6-di-behenate (TDB), a derivative with
lower toxicity of the mycobacterial trehalose dimycolate (TDM),
the crucial ingredient of cord factor (Gram et al., 2009). CAF01
allows for slow antigen release from a depot, maturation of
APCs, and stimulation of Th1, Th2, and Th17 cells, aswell as anti-
bodies and CD8+ CTL. The receptor for TDM and TDB has
recently been identified as the C-type lectin, MINCLE (Ishikawa
et al., 2009; Schoenen et al., 2010).
New antigens currently assessed for next generation TB
subunit vaccines include the heparin-binding hemagglutinin
(HBHA), a protein shared by Mtb and BCG but differentially
methylated (Rouanet et al., 2009). The HBHA is an adhesion
molecule for nonphagocytic cells and is involved in extrapulmo-
nary dissemination ofMtb (Pethe et al., 2001). Although HBHA is
a potent antigen, T cells, surprisingly, are specific for the meth-
ylated AA sequences (Locht et al., 2006). These post-transla-
tional modifications pose major obstacles for recombinant
production by bacteria different from Mtb. Recent research for
additional vaccine antigens focuses on dormancy and starvation
gene products such as the DosR-regulated proteins (Voskuil
et al., 2003; Betts et al., 2002; Black et al., 2009; Schuck et al.,
2009; Leyten et al., 2006; Lin and Ottenhoff, 2008).
Viable Vaccines to Replace BCG
Strategies to construct vaccines that can replace BCG try to
improve upon antigenicity, immunogenicity, or both (Grode
et al., 2005; Tullius et al., 2008). The rBCG30 developed by Hor-
witz and colleagues overexpresses Ag85B, which is shared by
BCG andMtb (Tullius et al., 2008). Higher abundance increases
its antigenicity. The rBCGDUreC:Hly vaccine developed by our
group has increased immunogenicity compared to BCG (Grode
et al., 2005). Hly (listeriolysin from Listeria monocytogenes) is
a component of this vaccine and perforates membranes but is
active only at acidic pH. Because BCG neutralizes phagosomal
pH, Hly cannot display its full biological activity there. This
required deletion of urease C (ureC), which, together with other
factors, is involved in pH neutralization in the phagosome. The
original strategem focused on improved antigen release into
the cytosol resulting in better CD8+ T cell stimulation. Recent
evidence suggests that membrane perforation also increases
apoptosis of host cells. This leads to the formation of apoptotic
vesicles that carry mycobacterial antigens as cargo. Uptake of
these vesicles by DCs allows cross-priming for superior CD4+
and CD8+ T cell stimulation (Winau et al., 2005). More recent
evidence suggests that this process can favor stimulation of
Th17 cells in addition to Th1 cells (Torchinsky et al., 2009).
Although the precise mechanisms underlying superior immuno-
genicity have not been fully elucidated, this vaccine strain
shows better protection in preclinical models not only against
the laboratory strain Mtb H37Rv but also against a member of
the clinically important Beijing genotype family (Grode et al.,
2005).Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 571
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compared to parental BCG as shown in different animal models
such as immunocompromised mice (Grode et al., 2005; Tullius
et al., 2008). Hence, they should already be safer in humans
than parental BCG. Further strategies to increase safety of
such vaccines include introduction of auxotrophy by deletion
of genes involved in biosynthesis of essential micronutrients
absent in the human host. Auxotrophic Mtb and BCG strains
include deficiencies in leucine, glutamine, methionine, lysine,
and pantothenate (Guleria et al., 1996; Sambandamurthy et al.,
2002; Bange et al., 1996). The first attenuated auxotrophic TB
vaccine candidates were generated in 1996 but never entered
clinical trials (Guleria et al., 1996). Safer vaccines to replace
BCG are of great importance. Increased incidence of dissemi-
nated BCGosis in HIV+ newborns leads to a serious disease
that can be lethal. This led to the recommendation of the World
Health Organization (WHO) against BCG vaccination of
newborns with proven HIV+ status (WHO, 2007).
Viable vaccine candidates in the R&D pipeline from preclinical
to Phase 1 clinical development include further modifications of
rBCG as well as attenuated rMtb strains. By building on the
strategy originally described by the Horwitz group, researchers
added either antigens that are absent in BCG (such as TB10.4)
or antigens already present in BCG that are being overexpressed
(such as Ag85A) (Sun et al., 2009). Our strategem of introducing
pore-forming capacities into BCG has been modified by replac-
ing Hly with perfringolysin (pfo) fromClostridium perfringens (Sun
et al., 2009). Combination of both strategies led to a vaccine
combining concomitant expression of pfo and the antigens
Ag85A, Ag85B, and TB10.4 (Sun et al., 2009, 2010). This vaccine
construct was safe and induced IFN-g-producing T cells in mice
but failed to induce substantially higher protection against TB
than parental BCG (Sun et al., 2009, 2010). Vaccines based on
Mtb attenuation must comprise at least two independent dele-
tions to avoid spontaneous conversion to virulence (Walker
et al., 2010). The most advanced candidates are Mtb DRD1,
DpanCD, which is devoid of the Mtb virulence gene cluster
RD1 and auxotrophic because of pantothenate deficiency (Sam-
bandamurthy et al., 2006), and Mtb DPhoPDfad (Martin et al.,
2006; C. Martin, personal communication). PhoP is part of the
two-component system PhoP plus PhoR, which is a transcrip-
tional regulator for numerous virulence factors. Mutation in
PhoP has been found critical for attenuation ofMtb H37Ra, orig-
inally derived fromH37Rv (Lee et al., 2008). The fad gene product
is essential for the synthesis of phthiocerol dimycocerosate
(C. Martin, personal communication).
Future strategies to improve efficacy of BCG replacement
candidates include introduction of (1) genes encoding dormancy
antigens such as the DosR-regulated gene products for post-
exposure vaccination of latently infected individuals (Lin et al.,
2007); (2) cytokine genes such as those for IL-18 and for IFN-g
for more profound Th1 cell polarization; and (3) deletion of anti-
apoptotic genes to facilitate cross-priming.
Is this sufficient or dowe needmore sophisticated vaccines? A
first attempt might be to combine current vaccine candidates to
achieve sterile eradication of the pathogen, i.e., prime with the
best BCG replacement vaccine followed by a selection of subunit
boosters. These vaccines would contain antigens secreted by
metabolically active Mtb as well as dormancy antigens.572 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.Vaccination Strategies of the Near Future
Pre-exposure vaccination strategies have to induce a memory
T cell response that resists exhaustion, suppression, and devia-
tion so that it remains in a stage of alertness, whereby immune
mechanisms can be promptly mobilized after encounter with
Mtb. Novel postexposure vaccines have to restimulate the
memory T cells induced by Mtb, promote potent Teff cells, and
prevent suppressive sequellae.
At stage 1.0, vaccine candidates that containMtb infection to
prevent TB disease outbreak require long-lasting memory T cell
responses comprising mostly CD4+ Th1 cells that activate
macrophages to control their intracellular predators within solid
granulomas. Because Mtb switches from a metabolically active
to a dormant stage under pressure of the immune response,
both dormancy and secreted antigens are needed (Black et al.,
2009; Schuck et al., 2009; Leyten et al., 2006; Lin and Ottenhoff,
2008). Even though all current vaccine candidates follow this line
of reasoning, the real-life situation is probably more complex.
The environmental microbiome of pathogens and commensals
may alter the ongoing immune response (Azzopardi et al.,
2009; Hesseling et al., 2007a; Mansoor et al., 2009; Wilson
et al., 1995; Weir et al., 2006; Hatherill et al., 2009). Humans,
particularly in countries with high TB prevalence, are constantly
exposed to various microorganisms. Environmental mycobacte-
ria can alter BCG-induced immunity (Wilson et al., 1995;
Weir et al., 2006); HIV impairs the CD4+ T cell compartment
resulting in increased susceptibility to Mtb (Azzopardi et al.,
2009; Hesseling et al., 2007a, 2007b; Mansoor et al., 2009),
and helminths drive the Th1 cell type response toward a Th2
cell type response, which can impair Th1 cell responses to Mtb
(Hatherill et al., 2009). Hence, in humans, vaccine-induced
immunity, which controls Mtb, is continuously exposed to
numerous confounding influences from the outside. Uninter-
rupted fine-tuning is required to maintain protective immunity
(Dorhoi and Kaufmann, 2009).
Internal influences may also confound protective immunity.
These include suppression by cytokines (IL-10, TGF-b) from
Treg cells or by soluble CD25, which acts as a decoy for IL-2,
as well as exhaustion through cognate signaling via PD-1-PD-
L1 or PD-L2 or CTLA-4-B7.1 or B7.2 (Chambers et al., 2001;
Keir et al., 2008; Belkaid and Tarbell, 2009; Rubin et al., 1985;
Shitrit et al., 2006; Jurado et al., 2008). Principally, these mech-
anisms are induced to avoid collateral damage by the ongoing
immune response after pathogen eradication. In the case of
TB, the pathogen is not eradicated and active TB disease is pre-
vented in the face of persistent Mtb. Apparently, this quandary
is hard to solve for the immune system. Recent findings in
virus systems indicate that IL-21 can counteract exhaustion
(Elsaesser et al., 2009; Fro¨hlich et al., 2009; Yi et al., 2009). Simi-
larly, the immunosuppressive drug rapamycin was recently
shown to stabilize memory T cell responses (Araki et al., 2009).
Thus, strategies to sustain memory responses should consider
blocking of inhibitory cytokines IL-10 and TGF- b or soluble
CD25 and inhibitory T cell coreceptors PD-1 and CTLA-4 as
well as prevention of inhibitory signals by use of cytokines
such as IL-21 or drugs such as rapamycin.
Finally, for efficacious control of latentMtb infection, canonical
memory is insufficient (i.e., continuous presence of memory
T cells that are reactivated after encounter with the pathogen).
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continuously over prolonged periods of time, often lifelong. In
sum, although the current vaccination R&D pipeline has come
up with several candidates, their ultimate efficacy in the real
world still needs to be proven. In fact, the task for these vaccine
candidates is not an easy one because they have to induce life-
long immunity, which contains Mtb in face of numerous con-
founding factors such as coinfection, suppression, and exhaus-
tion. Such vaccination strategies therefore need to consider
how to fine-tune long-lasting immunity in such a disorienting
scenario.
The Distant Future: Vaccines that Achieve Sterile
Eradication of Mtb
We now move forward to stage 2.0, namely, to vaccines that
achieve sterile eradication of the pathogen. Although this is
considered an essential requirement for most vaccines in use
today, it has not been explored successfully in the realm of TB.
Whichmechanisms of protective immunity should such vaccina-
tion schemes induce?
Let us start our deliberations with post-exposure vaccines,
which target the 2.2 billion individuals on this globe who are
presumably latently infected with Mtb. First, such a vaccine
should focus on antigens expressed by dormant Mtb in latently
infected individuals. Second, this vaccine should induce an
aggressive immune response against Mtb while minimizing
collateral tissue damage from amplification of the immune
response. On the positive side, the immune response could be
short-lived and wane after elimination of Mtb. It is probable that
such an immune responsewould best be achievedby stimulating
different T cell populations that attackMtb from multiple angles:
first, Th17 cells that attract granulocytes to the site ofMtb persis-
tence and create inflammation (Khader et al., 2007); second, Th1
cells that activate macrophages to eradicate their intracellular
predators (Kaufmann, 2006b); third, CD8+ CTL that assault
intracellular Mtb by concerted action of granulysin and perforin
(Stenger et al., 1997, 1998). Conventional T cells may be further
supported by unconventional T cells, with similar or complemen-
tary functions. Thus, animal experiments suggest that in TB, IL-17
is primarily produced by gd T cells (Lockhart et al., 2006), and
CD1-restricted T cells with specificity for glycolipids ofMtb share
several effector functions with CD4+ Th1 cells (Brigl and Brenner,
2004). Finally, antibodies could attack Mtb released into the
extracellular space during host cell destruction.
Thus far, emphasis was laid on elimination of dormant Mtb,
which is resistant to immune assault. It may be necessary to
resuscitate dormant bacteria first to render them more suscep-
tible to immune-mediated clearance. In this case, Mtb would
need to be attacked after resuscitation, promptly and heavily,
by the immune mechanisms described above.
Animal experiments as well as in vitro cell culture experiments
with human leukocytes should be performed to elucidate the
most potent mechanisms and how they could be combined to
achieve synergistic effects. It goes without saying that because
of the highly aggressive nature of the immune response, careful
risk assessment and monitoring of side effects are essential.
Because damage will occur only in infected individuals, safety
issues cannot be fully solved in Phase I trials with naive study
participants.As a next step, pre-exposure vaccines that aim at accomplish-
ing the same goals are desirable that can protect naive individ-
uals by rapid elimination of Mtb after infection. Although the
effector mechanisms are probably very similar, pre-exposure
vaccines in addition need to induce a long-lasting memory
response, which can be rapidly mobilized upon Mtb infection.
Moreover, these vaccines should include antigens produced
by metabolically activeMtb to allow attack promptly after stable
infection has been established.
Both scenarios would fail in HIV-coinfected individuals in
whom immunity cannot be stimulated at full strength. Finally,
confounding issues as described under stage 1.0 remain,
notably the risk of T cell exhaustion and the need for fine-tuning
in response to coinfection with environmental commensals and
pathogens.
The Distant Future: Vaccines that PreventMtb Infection
We now come to stage 3.0, a strategy of preventing infection by
the induction of pre-existing antibodies. This approach has little
precedent for TB. Yet, some vaccines (e.g., against human papil-
lomavirus) are based on pre-existing antibodies that eradicate
the pathogen before it can hide inside host cells, where it estab-
lishes stable infection to cause disease later (Stanley, 2010).
Only very few Mtb organisms enter the lung that would become
targets of antibodies preexisting in the alveolar space. These
antibodies should fulfill three tasks at least: first, neutralization
of essential functions in Mtb, e.g., uptake of iron and other
essential micronutrients (Schaible and Kaufmann, 2004);
second, stimulation of potent host effector mechanisms, i.e.,
activation of alveolar macrophages as well as attraction of blood
neutrophils and monocytes to the port of entry; third, prevention
of Mtb uptake by nonprofessional phagocytes, such as lung
parenchyma cells, and by professional phagocytes of insufficient
competence. Evidence exists that alveolar macrophages cannot
be activated to full antibacterial competence (Russi and Crystal,
1997; Geissmann et al., 2010). Hence, their role in TB needs to be
determined carefully: do they primarily perform as effectors
against or as refuge forMtb? Principally, antibodies bind to cells
via cognates of the Fc receptor (FcR) family (Nimmerjahn and
Ravetch, 2007). This family includes both inhibitory and stimula-
tory cognates. Ideally, vaccine-induced antibodies would acti-
vate effector cells through activating FcR and be prohibited
from binding to inhibitory FcR. Attack of Mtb by antibodies
should be accompanied by Th17 cells, which attract neutrophils,
and by Th1 cells, which in turn activate mononuclear phagocytes
(Cooper, 2009). Perhaps further help is required from CD8+ CTL,
which assault Mtb by the combined coercion of perforin and
granulysin (Stenger et al., 1997, 1998). Because this type of
aggressive blitzkrieg will ensue only after TB reactivation, moni-
toring for side effects needs to await Phase III trials, which
assess vaccine efficacy against natural Mtb infection. Phase I
and II trials comprising healthy uninfected or Mtb latently
infected individuals cannot provide full answers to these safety
issues.
Concluding Remarks
After decades of research, the R&D pipeline of TB vaccines is
ready to reap the fruits of its efforts. The number of vaccine
candidates that have entered the clinical trial pipeline exceedsImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 573
Immunity
Reviewthe financial resources available for clinical phase III trials
(Box 1), so attrition is called for. Although there is hope that within
the next decade one or two vaccines with proven protective
efficacy and safety may emerge, this by no means signals the
end of scientific efforts. All vaccine candidates currently under-
going clinical trials will only delay TB reactivation and hence
will depend on efficacious memory capable of controlling Mtb
in a dormant stage lifelong. Such long-lasting immunity, how-
ever, is prone to confounding effects, be they internal such as
regulation and exhaustion or external such as coinfection with
HIV or helminths. Hence, basic research needs to find alterna-
tives, such as sterile pathogen eradication or prevention of
stable infection. Experimental models provide novel information
as to how the immune response can be strengthened so that it is
superior to the natural immune response against Mtb infection,
and clinical trials will provide information about immunity evoked
by novel vaccine candidates. A full circle of translation of
experiments in the wetlab that reveal novel vaccine candidates
and reverse translation of findings in the field, which disclose
human-specific responses to vaccine candidates, is the best, if
not the only, stratagem to move forward to a vaccine that can
substantially reduce TB incidences to <1 case per million popu-
lation as ambitiously proposed by the StopTB Partnership, who
seeks elimination of TB by 2050 (Abu-Raddad et al., 2009; Dye
and Williams, 2008).ACKNOWLEDGMENTS
I thank M. Grossman for outstanding editorial support. I also thank D. Schad
for her outstanding graphic design of the figures. Many thanks to W. Hanekom
of Capetown, South Africa, and C. Martin of Zaragosa, Spain, for helpful
comments. I thank the many colleagues and friends with whom I have dis-
cussed future vaccination strategies against TB on many occasions, notably
members of the Tuberculosis Vaccine Initiative (TBVI) and members of the
Bill & Melinda Gates Foundation Grand Challenge 6 Program. Work from my
own laboratory on TB vaccine development receives financial support from
numerous sources, notably NEWTBVAC FP7 (HEALTH-F3-2009-241745)
and Bill & Melinda Gates Foundation Grand Challenges in Global Health (Grant
No. 37772). S.H.E.K. is coinventor of the rBCGDUreC:Hly vaccine candidate
and member of the Scientific Advisory Boards of Intercell and of Vaccine
Project Management (VPM).REFERENCES
Abu-Raddad, L.J., Sabatelli, L., Achterberg, J.T., Sugimoto, J.D., Longini, I.M.,
Jr., Dye, C., and Halloran, M.E. (2009). Epidemiological benefits of more-effec-
tive tuberculosis vaccines, drugs, and diagnostics. Proc. Natl. Acad. Sci. USA
106, 13980–13985.
Akira, S., Uematsu, S., and Takeuchi, O. (2006). Pathogen recognition and
innate immunity. Cell 124, 783–801.
Antas, P.R., and Castello-Branco, L.R. (2008). New vaccines against tubercu-
losis: Lessons learned from BCG immunisation in Brazil. Trans. R. Soc. Trop.
Med. Hyg. 102, 628–630.
Araki, K., Turner, A.P., Shaffer, V.O., Gangappa, S., Keller, S.A., Bachmann,
M.F., Larsen, C.P., and Ahmed, R. (2009). mTOR regulates memory CD8
T-cell differentiation. Nature 460, 108–112.
Azzopardi, P., Bennett, C.M., Graham, S.M., andDuke, T. (2009). Bacille Calm-
ette-Gue´rin vaccine-related disease in HIV-infected children: A systematic
review. Int. J. Tuberc. Lung Dis. 13, 1331–1344.
Bangari, D.S., and Mittal, S.K. (2006). Development of nonhuman adenovi-
ruses as vaccine vectors. Vaccine 24, 849–862.574 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.Bange, F.C., Brown, A.M., and Jacobs, W.R., Jr. (1996). Leucine auxotrophy
restricts growth ofMycobacterium bovis BCG in macrophages. Infect. Immun.
64, 1794–1799.
Belkaid, Y., and Tarbell, K. (2009). Regulatory T cells in the control of host-
microorganism interactions (*). Annu. Rev. Immunol. 27, 551–589.
Betts, J.C., Lukey, P.T., Robb, L.C., McAdam, R.A., and Duncan, K. (2002).
Evaluation of a nutrient starvation model of Mycobacterium tuberculosis
persistence by gene and protein expression profiling. Mol. Microbiol. 43,
717–731.
Black, G.F., Thiel, B.A., Ota, M.O., Parida, S.K., Adegbola, R., Boom, W.H.,
Dockrell, H.M., Franken, K.L., Friggen, A.H., Hill, P.C., et al; GCGHBiomarkers
for TB Consortium. (2009). Immunogenicity of novel DosR regulon-encoded
candidate antigens of Mycobacterium tuberculosis in three high-burden pop-
ulations in Africa. Clin. Vaccine Immunol. 16, 1203–1212.
Brigl, M., and Brenner, M.B. (2004). CD1: Antigen presentation and T cell func-
tion. Annu. Rev. Immunol. 22, 817–890.
Calmette, A. (1927). Sur la vaccination pre´ventive des enfants nouveau-ne´s
contre la tuberculose par le BCG. Annales de l‘Institut Pasteur 41, 201–232.
Chambers, C.A., Kuhns, M.S., Egen, J.G., and Allison, J.P. (2001). CTLA-4-
mediated inhibition in regulation of T cell responses: Mechanisms and manip-
ulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565–594.
Chen, X., Zhou, B., Li, M., Deng, Q., Wu, X., Le, X., Wu, C., Larmonier, N.,
Zhang, W., Zhang, H., et al. (2007). CD4(+)CD25(+)FoxP3(+) regulatory
T cells suppressMycobacterium tuberculosis immunity in patients with active
disease. Clin. Immunol. 123, 50–59.
Cooper, A.M. (2009). Cell-mediated immune responses in tuberculosis. Annu.
Rev. Immunol. 27, 393–422.
Cosma, C.L., Humbert, O., Sherman, D.R., and Ramakrishnan, L. (2008). Traf-
ficking of superinfecting Mycobacterium organisms into established granu-
lomas occurs in mammals and is independent of the Erp and ESX-1 mycobac-
terial virulence loci. J. Infect. Dis. 198, 1851–1855.
Davis, J.M., and Ramakrishnan, L. (2009). The role of the granuloma in expan-
sion and dissemination of early tuberculous infection. Cell 136, 37–49.
Day, T.A., Koch, M., Nouailles, G., Jacobsen, M., Kosmiadi, G.A., Miekley, D.,
Kuhlmann, S., Jo¨rg, S., Gamradt, P., Mollenkopf, H.J., et al. (2010). Secondary
lymphoid organs are dispensable for the development of T-cell-mediated
immunity during tuberculosis. Eur. J. Immunol. 40, 1663–1673.
Dennehy, K.M., Willment, J.A., Williams, D.L., and Brown, G.D. (2009). Recip-
rocal regulation of IL-23 and IL-12 following co-activation of Dectin-1 and TLR
signaling pathways. Eur. J. Immunol. 39, 1379–1386.
Deretic, V. (2006). Autophagy as an immune defense mechanism. Curr. Opin.
Immunol. 18, 375–382.
Dietrich, J., Aagaard, C., Leah, R., Olsen, A.W., Stryhn, A., Doherty, T.M., and
Andersen, P. (2005). Exchanging ESAT6 with TB10.4 in an Ag85B fusion mole-
cule-based tuberculosis subunit vaccine: Efficient protection and ESAT6-
based sensitive monitoring of vaccine efficacy. J. Immunol. 174, 6332–6339.
Divangahi, M., Desjardins, D., Nunes-Alves, C., Remold, H.G., and Behar, S.M.
(2010). Eicosanoid pathways regulate adaptive immunity to Mycobacterium
tuberculosis. Nat. Immunol. 11, 751–758.
Dlugovitzky, D., Bay, M.L., Rateni, L., Urı´zar, L., Rondelli, C.F., Largacha, C.,
Farroni, M.A., Molteni, O., and Bottasso, O.A. (1999). In vitro synthesis of inter-
feron-gamma, interleukin-4, transforming growth factor-beta and interleukin-1
beta by peripheral blood mononuclear cells from tuberculosis patients: Rela-
tionship with the severity of pulmonary involvement. Scand. J. Immunol. 49,
210–217.
Dorhoi, A., and Kaufmann, S.H. (2009). Fine-tuning of T cell responses during
infection. Curr. Opin. Immunol. 21, 367–377.
Dorhoi,A., Desel,C., Yeremeev, V.V., Pradl, L., Brinkmann,V.,Mollenkopf,H.-J.,
Hanke, K., Gross, O., Ruland, J., and Kaufmann, S.H.E. (2010). The adaptor
moleculeCARD9 isessential for tuberculosiscontrol. J.Exp.Med.207, 777–792.
Dye, C., and Williams, B.G. (2008). Eliminating human tuberculosis in the
twenty-first century. J. R. Soc. Interface 5, 653–662.
Immunity
ReviewElsaesser, H., Sauer, K., and Brooks, D.G. (2009). IL-21 is required to control
chronic viral infection. Science 324, 1569–1572.
Fine, P.E. (1995). Variation in protection by BCG: Implications of and for heter-
ologous immunity. Lancet 346, 1339–1345.
Flatz, L., Hegazy, A.N., Bergthaler, A., Verschoor, A., Claus, C., Fernandez, M.,
Gattinoni, L., Johnson, S., Kreppel, F., Kochanek, S., et al. (2010). Develop-
ment of replication-defective lymphocytic choriomeningitis virus vectors for
the induction of potent CD8+ T cell immunity. Nat. Med. 16, 339–345.
Foulds, K.E., Wu, C.Y., and Seder, R.A. (2006). Th1 memory: Implications for
vaccine development. Immunol. Rev. 211, 58–66.
Fro¨hlich, A., Kisielow, J., Schmitz, I., Freigang, S., Shamshiev, A.T., Weber, J.,
Marsland, B.J., Oxenius, A., and Kopf, M. (2009). IL-21R on T cells is critical for
sustained functionality and control of chronic viral infection. Science 324,
1576–1580.
Gandhi, N.R., Nunn, P., Dheda, K., Schaaf, H.S., Zignol, M., van Soolingen, D.,
Jensen, P., and Bayona, J. (2010). Multidrug-resistant and extensively drug-
resistant tuberculosis: A threat to global control of tuberculosis. Lancet 375,
1830–1843.
Geijtenbeek, T.B., Van Vliet, S.J., Koppel, E.A., Sanchez-Hernandez, M., Van-
denbroucke-Grauls, C.M., Appelmelk, B., and Van Kooyk, Y. (2003). Mycobac-
teria targetDC-SIGN tosuppressdendriticcell function. J. Exp.Med.197, 7–17.
Geissmann, F., Manz, M.G., Jung, S., Sieweke, M.H., Merad, M., and Ley, K.
(2010). Development of monocytes, macrophages, and dendritic cells.
Science 327, 656–661.
Gram, G.J., Karlsson, I., Agger, E.M., Andersen, P., and Fomsgaard, A. (2009).
A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic
T-lymphocytes (CTL) to HIV-1minimal CTL peptides in HLA-A*0201 transgenic
mice. PLoS ONE 4, e6950.
Grode, L., Seiler, P., Baumann, S., Hess, J., Brinkmann, V., Nasser Eddine, A.,
Mann, P., Goosmann, C., Bandermann, S., Smith, D., et al. (2005). Increased
vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis
bacille Calmette-Gue´rin mutants that secrete listeriolysin. J. Clin. Invest.
115, 2472–2479.
Guleria, I., Teitelbaum, R., McAdam, R.A., Kalpana, G., Jacobs, W.R., Jr., and
Bloom,B.R. (1996).Auxotrophicvaccines for tuberculosis.Nat.Med.2, 334–337.
Gutierrez, M.G., Master, S.S., Singh, S.B., Taylor, G.A., Colombo, M.I., and
Deretic, V. (2004). Autophagy is a defense mechanism inhibiting BCG and
Mycobacterium tuberculosis survival in infected macrophages. Cell 119,
753–766.
Guyot-Revol, V., Innes, J.A., Hackforth, S., Hinks, T., and Lalvani, A. (2006).
Regulatory T cells are expanded in blood and disease sites in patients with
tuberculosis. Am. J. Respir. Crit. Care Med. 173, 803–810.
Harding, C.V., and Boom, W.H. (2010). Regulation of antigen presentation by
Mycobacterium tuberculosis: A role for Toll-like receptors. Nat. Rev. Microbiol.
8, 296–307.
Harries, A.D., Zachariah, R., Corbett, E.L., Lawn, S.D., Santos-Filho, E.T.,
Chimzizi, R., Harrington, M., Maher, D., Williams, B.G., and De Cock, K.M.
(2010). The HIV-associated tuberculosis epidemic—When will we act? Lancet
375, 1906–1919.
Hatherill, M., Adams, V., Hughes, J., De Kock, M., Mavakla, W., Pienaar, B.,
Mahomed, H., Hussey, G., and Hanekom, W.A. (2009). The potential impact
of helminth infection on trials of novel tuberculosis vaccines. Vaccine 27,
4743–4744.
Hesseling, A.C., Cotton, M.F., Marais, B.J., Gie, R.P., Schaaf, H.S., Beyers, N.,
Fine, P.E., Abrams, E.J., Godfrey-Faussett, P., and Kuhn, L. (2007a). BCG and
HIV reconsidered:Moving the researchagenda forward. Vaccine25, 6565–6568.
Hesseling, A.C., Marais, B.J., Gie, R.P., Schaaf, H.S., Fine, P.E., Godfrey-
Faussett, P., and Beyers, N. (2007b). The risk of disseminated Bacille Calm-
ette-Guerin (BCG) disease in HIV-infected children. Vaccine 25, 14–18.
Hill, A.V., Reyes-Sandoval, A., O’Hara, G., Ewer, K., Lawrie, A., Goodman, A.,
Nicosia, A., Folgori, A., Colloca, S., Cortese, R., et al. (2010). Prime-boost
vectored malaria vaccines: Progress and prospects. Hum. Vaccin. 6, 78–83.Hotez, P.J., and Kamath, A. (2009). Neglected tropical diseases in sub-sa-
haran Africa: Review of their prevalence, distribution, and disease burden.
PLoS Negl. Trop. Dis. 3, e412.
Hutnick, N.A., Carnathan, D.G., Dubey, S.A., Makedonas, G., Cox, K.S.,
Kierstead, L., Ratcliffe, S.J., Robertson, M.N., Casimiro, D.R., Ertl, H.C., and
Betts, M.R. (2009). Baseline Ad5 serostatus does not predict Ad5 HIV
vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat. Med.
15, 876–878.
Ishikawa, E., Ishikawa, T., Morita, Y.S., Toyonaga, K., Yamada, H., Takeuchi,
O., Kinoshita, T., Akira, S., Yoshikai, Y., and Yamasaki, S. (2009). Direct recog-
nition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin
Mincle. J. Exp. Med. 206, 2879–2888.
Jurado, J.O., Alvarez, I.B., Pasquinelli, V., Martı´nez, G.J., Quiroga, M.F., Ab-
bate, E., Musella, R.M., Chuluyan, H.E., and Garcı´a, V.E. (2008). Programmed
death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions
during human tuberculosis. J. Immunol. 181, 116–125.
Kagina, M.N., Abel, B., Scriba, T.J., Hughes, E.J., Keyser, A., Soares, A., Ga-
mieldien, H., Sidibana, M., Hatherill, M., Gelderbloem, S., Mahomed, H.,
Hawkridge, A., Hussey, G., Kaplan, G., and Hanekom, M., and other members
of SATVI. (2010). Specific T cell frequency and cytokine expression profile do
not correlate with protection against tuberculosis, following BCG vaccination
of newborns. Am. J. Respir. Crit. Care Med., in press. Published online June
17, 2010. 10.1164/rccm.201003-0334OC.
Kana, B.D., Gordhan, B.G., Downing, K.J., Sung, N., Vostroktunova, G.,
Machowski, E.E., Tsenova, L., Young, M., Kaprelyants, A., Kaplan, G., and
Mizrahi, V. (2008). The resuscitation-promoting factors of Mycobacterium
tuberculosis are required for virulence and resuscitation from dormancy but
are collectively dispensable for growth in vitro. Mol. Microbiol. 67, 672–684.
Kaufmann, S.H.E. (2006a). Envisioning future strategies for vaccination against
tuberculosis. Nat. Rev. Immunol. 6, 699–704.
Kaufmann, S.H.E. (2006b). Tuberculosis: Back on the immunologists’ agenda.
Immunity 24, 351–357.
Kaufmann, S.H.E. (2009). The New Plagues: Pandemics and Poverty in a Glob-
alized World (London: Haus Publishing).
Kaufmann, S.H., Hussey, G., and Lambert, P.H. (2010). New vaccines for
tuberculosis. Lancet 375, 2110–2119.
Keir, M.E., Butte, M.J., Freeman, G.J., and Sharpe, A.H. (2008). PD-1 and its
ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704.
Khader, S.A., Bell, G.K., Pearl, J.E., Fountain, J.J., Rangel-Moreno, J., Cilley,
G.E., Shen, F., Eaton, S.M., Gaffen, S.L., Swain, S.L., et al. (2007). IL-23 and IL-
17 in the establishment of protective pulmonary CD4+ T cell responses after
vaccination and duringMycobacterium tuberculosis challenge. Nat. Immunol.
8, 369–377.
Kursar, M., Koch, M., Mittru¨cker, H.W., Nouailles, G., Bonhagen, K., Kamradt,
T., and Kaufmann, S.H. (2007). Cutting Edge: Regulatory T cells prevent effi-
cient clearance of Mycobacterium tuberculosis. J. Immunol. 178, 2661–2665.
Lee, J.S., Krause, R., Schreiber, J., Mollenkopf, H.J., Kowall, J., Stein, R.,
Jeon, B.Y., Kwak, J.Y., Song, M.K., Patron, J.P., et al. (2008). Mutation in
the transcriptional regulator PhoP contributes to avirulence ofMycobacterium
tuberculosis H37Ra strain. Cell Host Microbe 3, 97–103.
Leyten, E.M., Lin, M.Y., Franken, K.L., Friggen, A.H., Prins, C., van Meijgaar-
den, K.E., Voskuil, M.I., Weldingh, K., Andersen, P., Schoolnik, G.K., et al.
(2006). Human T-cell responses to 25 novel antigens encoded by genes of
the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect. 8,
2052–2060.
Lin, M.Y., and Ottenhoff, T.H. (2008). Not to wake a sleeping giant: New
insights into host-pathogen interactions identify new targets for vaccination
against latent Mycobacterium tuberculosis infection. Biol. Chem. 389,
497–511.
Lin, M.Y., Geluk, A., Smith, S.G., Stewart, A.L., Friggen, A.H., Franken, K.L.,
Verduyn, M.J., van Meijgaarden, K.E., Voskuil, M.I., Dockrell, H.M., et al.
(2007). Lack of immune responses to Mycobacterium tuberculosis DosR reg-
ulon proteins followingMycobacterium bovis BCG vaccination. Infect. Immun.
75, 3523–3530.Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 575
Immunity
ReviewLingnau, K., Riedl, K., and von Gabain, A. (2007). IC31 and IC30, novel types of
vaccine adjuvant based on peptide delivery systems. Expert Rev. Vaccines 6,
741–746.
Locht, C., Hougardy, J.M., Rouanet, C., Place, S., and Mascart, F. (2006).
Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor
to a powerful diagnostic and protective antigen against tuberculosis. Tubercu-
losis (Edinb.) 86, 303–309.
Lockhart, E., Green, A.M., and Flynn, J.L. (2006). IL-17 production is domi-
nated by gammadelta T cells rather than CD4 T cells during Mycobacterium
tuberculosis infection. J. Immunol. 177, 4662–4669.
Lo¨nnroth, K., Castro, K.G., Chakaya, J.M., Chauhan, L.S., Floyd, K., Glaziou,
P., and Raviglione, M.C. (2010). Tuberculosis control and elimination 2010-
50: Cure, care, and social development. Lancet 375, 1814–1829.
Mansoor, N., Scriba, T.J., de Kock, M., Tameris, M., Abel, B., Keyser, A., Little,
F., Soares, A., Gelderbloem, S., Mlenjeni, S., et al. (2009). HIV-1 infection in
infants severely impairs the immune response induced by Bacille Calmette-
Gue´rin vaccine. J. Infect. Dis. 199, 982–990.
Martin, C., Williams, A., Hernandez-Pando, R., Cardona, P.J., Gormley, E.,
Bordat, Y., Soto, C.Y., Clark, S.O., Hatch, G.J., Aguilar, D., et al. (2006). The
live Mycobacterium tuberculosis phoP mutant strain is more attenuated than
BCG and confers protective immunity against tuberculosis in mice and guinea
pigs. Vaccine 24, 3408–3419.
McShane, H., Pathan, A.A., Sander, C.R., Keating, S.M., Gilbert, S.C., Huygen,
K., Fletcher, H.A., and Hill, A.V. (2004). Recombinant modified vaccinia virus
Ankara expressing antigen 85A boosts BCG-primed and naturally acquired
antimycobacterial immunity in humans. Nat. Med. 10, 1240–1244.
Mora, J.R., and von Andrian, U.H. (2006). T-cell homing specificity and plas-
ticity: New concepts and future challenges. Trends Immunol. 27, 235–243.
Nimmerjahn, F., and Ravetch, J.V. (2007). Fc-receptors as regulators of immu-
nity. Adv. Immunol. 96, 179–204.
O’Brien, K.L., Liu, J., King, S.L., Sun, Y.H., Schmitz, J.E., Lifton, M.A., Hutnick,
N.A., Betts, M.R., Dubey, S.A., Goudsmit, J., et al. (2009). Adenovirus-specific
immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.
Nat. Med. 15, 873–875.
O’Shea, J.J., and Paul, W.E. (2010). Mechanisms underlying lineage commit-
ment and plasticity of helper CD4+ T cells. Science 327, 1098–1102.
Parida, S.K., and Kaufmann, S.H. (2010). The quest for biomarkers in tubercu-
losis. Drug Discov. Today 15, 148–157.
Pethe, K., Alonso, S., Biet, F., Delogu, G., Brennan, M.J., Locht, C., and Me-
nozzi, F.D. (2001). The heparin-binding haemagglutinin of M. tuberculosis is
required for extrapulmonary dissemination. Nature 412, 190–194.
Radosevic, K., Wieland, C.W., Rodriguez, A., Weverling, G.J., Mintardjo, R.,
Gillissen, G., Vogels, R., Skeiky, Y.A., Hone, D.M., Sadoff, J.C., et al. (2007).
Protective immune responses to a recombinant adenovirus type 35 tubercu-
losis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping
and role of gamma interferon. Infect. Immun. 75, 4105–4115.
Reed, S.G., Bertholet, S., Coler, R.N., and Friede, M. (2009). New horizons in
adjuvants for vaccine development. Trends Immunol. 30, 23–32.
Rouanet, C., Debrie, A.S., Lecher, S., and Locht, C. (2009). Subcutaneous
boosting with heparin binding haemagglutinin increases BCG-induced protec-
tion against tuberculosis. Microbes Infect. 11, 995–1001.
Rubin, L.A., Kurman, C.C., Fritz, M.E., Biddison, W.E., Boutin, B., Yarchoan,
R., and Nelson, D.L. (1985). Soluble interleukin 2 receptors are released
from activated human lymphoid cells in vitro. J. Immunol. 135, 3172–3177.
Russell, D.G. (2007). Who puts the tubercle in tuberculosis? Nat. Rev. Micro-
biol. 5, 39–47.
Russi, T.J., and Crystal, R.G. (1997). Use of bronchoalvaeolar lavage and
airway brushing to investigate the human lung. In The Lung: Scientific Founda-
tions, R.G. Crystal, J.B. West, P.J. Barnes, and E. Weibel, eds. (Philadelphia:
Lippincott-Raven Publishers), pp. 371–382.
Sallusto, F., Geginat, J., and Lanzavecchia, A. (2004). Central memory and
effector memory T cell subsets: Function, generation, and maintenance.
Annu. Rev. Immunol. 22, 745–763.576 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.Sambandamurthy, V.K., Wang, X., Chen, B., Russell, R.G., Derrick, S., Collins,
F.M., Morris, S.L., and Jacobs, W.R., Jr. (2002). A pantothenate auxotroph of
Mycobacterium tuberculosis is highly attenuated and protects mice against
tuberculosis. Nat. Med. 8, 1171–1174.
Sambandamurthy, V.K., Derrick, S.C., Hsu, T., Chen, B., Larsen, M.H., Jalapa-
thy, K.V., Chen, M., Kim, J., Porcelli, S.A., Chan, J., et al. (2006). Mycobacte-
rium tuberculosis DeltaRD1 DeltapanCD: A safe and limited replicating mutant
strain that protects immunocompetent and immunocompromised mice
against experimental tuberculosis. Vaccine 24, 6309–6320.
Sander, C.R., Pathan, A.A., Beveridge, N.E., Poulton, I., Minassian, A., Alder, N.,
VanWijgerden, J., Hill, A.V., Gleeson, F.V., Davies, R.J., et al. (2009). Safety and
immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium
tuberculosis-infected individuals. Am. J. Respir. Crit. Care Med. 179, 724–733.
Santosuosso, M., McCormick, S., Zhang, X., Zganiacz, A., and Xing, Z. (2006).
Intranasal boosting with an adenovirus-vectored vaccine markedly enhances
protection by parenteral Mycobacterium bovis BCG immunization against
pulmonary tuberculosis. Infect. Immun. 74, 4634–4643.
Schaible, U.E., and Kaufmann, S.H.E. (2004). Iron and microbial infection. Nat.
Rev. Microbiol. 2, 946–953.
Schoenen, H., Bodendorfer, B., Hitchens, K., Manzanero, S., Werninghaus, K.,
Nimmerjahn, F., Agger, E.M., Stenger, S., Andersen, P., Ruland, J., et al.
(2010). Cutting edge: Mincle is essential for recognition and adjuvanticity of
the mycobacterial cord factor and its synthetic analog trehalose-dibehenate.
J. Immunol. 184, 2756–2760.
Schuck, S.D., Mueller, H., Kunitz, F., Neher, A., Hoffmann, H., Franken, K.L.,
Repsilber, D., Ottenhoff, T.H., Kaufmann, S.H., and Jacobsen, M. (2009). Iden-
tification of T-cell antigens specific for latent mycobacterium tuberculosis
infection. PLoS ONE 4, e5590.
Scotet, E., Nedellec, S., Devilder, M.C., Allain, S., and Bonneville, M. (2008).
Bridging innate and adaptive immunity through gammadelta T-dendritic cell
crosstalk. Front. Biosci. 13, 6872–6885.
Shitrit, D., Izbicki, G., Bar-Gil Shitrit, A., Raz, M., Sulkes, J., and Kramer, M.R.
(2006). Role of soluble interleukin-2 receptor levels in patients with latent
tuberculosis. Lung 184, 21–24.
Stanley, M. (2010). Prospects for new human papillomavirus vaccines. Curr.
Opin. Infect. Dis. 23, 70–75.
Stenger, S., Mazzaccaro, R.J., Uyemura, K., Cho, S., Barnes, P.F., Rosat, J.P.,
Sette, A., Brenner, M.B., Porcelli, S.A., Bloom, B.R., and Modlin, R.L. (1997).
Differential effects of cytolytic T cell subsets on intracellular infection. Science
276, 1684–1687.
Stenger, S., Hanson, D.A., Teitelbaum, R., Dewan, P., Niazi, K.R., Froelich,
C.J., Ganz, T., Thoma-Uszynski, S., Melia´n, A., Bogdan, C., et al. (1998). An
antimicrobial activity of cytolytic T cells mediated by granulysin. Science
282, 121–125.
StopTB Partnership Working Group on New TB Vaccines. (2009). StopTB
Tuberculosis Vaccine Pipeline 2009. http://www.stoptb.org/wg/
new_vaccines/assets/documents/TB%20Vaccine%20Pipeline%202009.pdf.
Sun, R., Skeiky, Y.A., Izzo, A., Dheenadhayalan, V., Imam, Z., Penn, E., Sta-
gliano, K., Haddock, S., Mueller, S., Fulkerson, J., et al. (2009). Novel recombi-
nant BCG expressing perfringolysin O and the over-expression of key immu-
nodominant antigens; pre-clinical characterization, safety and protection
against challenge with Mycobacterium tuberculosis. Vaccine 27, 4412–4423.
Sun, R., Hone, D. M., and Sadoff, J. C. February 2010.Recombinant BCG
strains with enhanced ability to escape the endosome. U.S. patent 7,666,656.
Sutherland, J.S., Young, J.M., Peterson, K.L., Sanneh, B., Whittle, H.C., Row-
land-Jones, S.L., Adegbola, R.A., Jaye, A., and Ota, M.O. (2010). Polyfunc-
tional CD4(+) and CD8(+) T cell responses to tuberculosis antigens in HIV-1-
infected patients before and after anti-retroviral treatment. J. Immunol. 184,
6537–6544.
Tailleux, L., Schwartz, O., Herrmann, J.L., Pivert, E., Jackson, M., Amara, A.,
Legres, L., Dreher, D., Nicod, L.P., Gluckman, J.C., et al. (2003). DC-SIGN is
the major Mycobacterium tuberculosis receptor on human dendritic cells.
J. Exp. Med. 197, 121–127.
Toossi, Z., and Ellner, J.J. (1998). Host response to Mycobacterium tubercu-
losis. Front. Biosci. 3, e133–e140.
Immunity
ReviewTorchinsky, M.B., Garaude, J., Martin, A.P., and Blander, J.M. (2009). Innate
immune recognition of infected apoptotic cells directs T(H)17 cell differentia-
tion. Nature 458, 78–82.
Tullius, M.V., Harth, G., Maslesa-Galic, S., Dillon, B.J., and Horwitz, M.A.
(2008). A replication-limited recombinant Mycobacterium bovis BCG vaccine
against tuberculosis designed for human immunodeficiency virus-positive
persons is safer and more efficacious than BCG. Infect. Immun. 76, 5200–
5214.
Ulrichs, T., and Kaufmann, S.H.E. (2006). New insights into the function of
granulomas in human tuberculosis. J. Pathol. 208, 261–269.
Underhill, D.M., Ozinsky, A., Smith, K.D., and Aderem, A. (1999). Toll-like
receptor-2 mediates mycobacteria-induced proinflammatory signaling in
macrophages. Proc. Natl. Acad. Sci. USA 96, 14459–14463.
van der Wel, N., Hava, D., Houben, D., Fluitsma, D., van Zon, M., Pierson, J.,
Brenner, M., and Peters, P.J. (2007).M. tuberculosis andM. leprae translocate
from the phagolysosome to the cytosol in myeloid cells. Cell 129, 1287–1298.
van Dissel, J.T., Arend, S.M., Prins, C., Bang, P., Tingskov, P.N., Lingnau, K.,
Nouta, J., Klein, M.R., Rosenkrands, I., Ottenhoff, T.H., et al. (2010). Ag85B-
ESAT-6 adjuvanted with IC31 promotes strong and long-livedMycobacterium
tuberculosis specific T cell responses in naı¨ve human volunteers. Vaccine 28,
3571–3581.
Volkman, H.E., Pozos, T.C., Zheng, J., Davis, J.M., Rawls, J.F., and Ramak-
rishnan, L. (2010). Tuberculous granuloma induction via interaction of a bacte-
rial secreted protein with host epithelium. Science 327, 466–469.
Von Eschen, K., Morrison, R., Braun, M., Ofori-Anyinam, O., De Kock, E.,
Pavithran, P., Koutsoukos, M., Moris, P., Cain, D., Dubois, M.-C., et al.
(2009). The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and
immunogenicity in humans. Hum. Vaccin. 5, 475–482.
Voskuil, M.I., Schnappinger, D., Visconti, K.C., Harrell, M.I., Dolganov, G.M.,
Sherman, D.R., and Schoolnik, G.K. (2003). Inhibition of respiration by nitric
oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp.
Med. 198, 705–713.Walker, K.B., Brennan, M.J., Ho, M.M., Eskola, J., Thiry, G., Sadoff, J., Dobbe-
laer, R., Grode, L., Liu, M.A., Fruth, U., and Lambert, P.H. (2010). The second
Geneva Consensus: Recommendations for novel live TB vaccines. Vaccine
28, 2259–2270.
Wayne, L.G., and Sohaskey, C.D. (2001). Nonreplicating persistence ofmyco-
bacterium tuberculosis. Annu. Rev. Microbiol. 55, 139–163.
Weir, R.E., Black, G.F., Nazareth, B., Floyd, S., Stenson, S., Stanley, C., Bran-
son, K., Sichali, L., Chaguluka, S.D., Donovan, L., et al. (2006). The influence of
previous exposure to environmental mycobacteria on the interferon-gamma
response to bacille Calmette-Gue´rin vaccination in southern England and
northern Malawi. Clin. Exp. Immunol. 146, 390–399.
WHO. (2007). Revised BCG vaccination guidelines for infants at risk for HIV
infection. Wkly. Epidemiol. Rec. 82, 193–196.
WHO. (2009). Global Tuberculosis Control: Epidemiology, Strategy, Financing.
WHO Report 2009 (Geneva: World Health Organization).
Williams, M.A., and Bevan, M.J. (2007). Effector and memory CTL differentia-
tion. Annu. Rev. Immunol. 25, 171–192.
Wilson, M.E., Fineberg, H.V., and Colditz, G.A. (1995). Geographic latitude and
the efficacy of bacillus Calmette-Gue´rin vaccine. Clin. Infect. Dis. 20, 982–991.
Winau, F., Hegasy, G., Kaufmann, S.H.E., and Schaible, U.E. (2005). No life
without death—Apoptosis as prerequisite for T cell activation. Apoptosis 10,
707–715.
Winau, F., Weber, S., Sad, S., de Diego, J., Hoops, S.L., Breiden, B., Sandhoff,
K., Brinkmann, V., Kaufmann, S.H.E., and Schaible, U.E. (2006). Apoptotic
vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity
24, 105–117.
Yi, J.S., Du, M., and Zajac, A.J. (2009). A vital role for interleukin-21 in the
control of a chronic viral infection. Science 324, 1572–1576.Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 577
